Cancer, Posttransplantation


Article Author:
Shekhar Gogna


Article Editor:
Savio John


Editors In Chief:
Wanda Wright
Cynthia Oster


Managing Editors:
Avais Raja
Orawan Chaigasame
Carrie Smith
Abdul Waheed
Khalid Alsayouri
Trevor Nezwek
Radia Jamil
Patrick Le
Anoosh Zafar Gondal
Saad Nazir
William Gossman
Hassam Zulfiqar
Steve Bhimji
John Shell
Matthew Varacallo
Heba Mahdy
Ahmad Malik
Sarosh Vaqar
Mark Pellegrini
James Hughes
Beata Beatty
Nazia Sadiq
Hajira Basit
Phillip Hynes
Tehmina Warsi


Updated:
1/25/2019 5:26:36 PM

Introduction

Organ transplant is the only way to extend the lives of many patients with end-stage organ failure. This procedure is not without the associated risks involved since the time of its inception. Cancer is one of the three major causes of death after an organ transplant.[1] Cardiovascular disease and infection are the other two reasons for death after an organ transplant, but they both are decreasing in frequency because of effective screening, prophylaxis, and interventional therapies. Understanding of post-transplant malignancy is inadequate regarding early detection and lack of established guidelines. The risk factor is most elusive because of altered dynamics of immunity, host response, and different clinical presentation.  Studies have shown an overall two to four-fold elevated risk of cancer after the organ transplant.[2] The mechanisms involved in the oncogenesis are long-term immunosuppression leading to reduced immune surveillance of neoplastic cells, and the opportunistic post-transplant infections especially viral infections because of EBV, Varicella, CMV, and HHV-8, etc.[3] Physicians and patients face a challenging problem that cancer after an organ transplant is more biologically aggressive and patients may receive less aggressive cancer treatment because of comorbidities and the fear of transplant rejection. In this article, we will discuss the epidemiology, pathophysiology, presentation, diagnosis, screening and treatment strategy for cancer after organ transplantation.

Etiology

The risk factors for post-transplant malignancy are the patient, transplant, and medication-related

1. Patient-related risk factors:  The advanced age of the patient is a well-described risk factor, and it is an established risk factor for the development of skin cancer. Sun exposure, prior history of cancer in a transplant recipient are also strong risk factors. Acuna et al. in their meta-analysis showed that pre-transplant malignancy correlates with an increased risk of cancer-specific mortality and of developing de novo malignancies after transplantation, compared with solid organ transplant recipients without a pretransplant malignancy.[4]  Smoking and alcohol consumption are risk factors for carcinogenesis and carry a high risk of mortality.[5] Viruses implicated in carcinogenesis include Epstein-Barr virus (EBV), human herpesvirus 8 (HHV-8), human papillomavirus (HPV), the Merkel cell polyomavirus, hepatitis B, and hepatitis C. EBV is implicated in the development of Hodgkin's disease, Non-Hodgkin lymphoma, and other manifestations of PTLD, nasopharyngeal cancers and leiomyosarcomas.[6]

2. Transplant-related risk factors: Differences in the type of transplant (living versus deceased) correlates with cancer risk. Patients who receive kidneys from a living donor have a lower risk for genitourinary cancer and PTLD.[7] Donor transmission as a cause of post-transplant malignancy is a rare but is a documented way of carcinogenesis; melanoma, cancer of lung, breast, colon, rectum, kidney, Kaposi sarcoma, and glioblastoma multiforme all have been reported to be transmittable from donors.[8] 

3. Medication-related risk factors:  The immunosuppressive drugs impair immunosurveillance of neoplastic cells and increase the incidence of virally induced malignancies. The type, intensity, and duration of immunosuppressive therapy all influence the rate of carcinogenesis. These immunosuppressive drugs, for example, biologic agents (anti-thymocyte globulin, basiliximab), corticosteroids, antimetabolites (azathioprine, mycophenolate mofetil), calcineurin inhibitors (cyclosporine, tacrolimus), and mTOR inhibitors (rapamycin [sirolimus], everolimus) all have been implicated.[9]

Epidemiology

The Israel Penn International Transplant Tumor Registry (IPITTR),[10] the largest and most comprehensive registry in the world records non-melanoma skin cancers (NMSCs) as the most prevalent cancer in post organ transplant state. Following is the list of various cancers associated with the organ transplant:

  • Kaposi sarcoma
  • Skin (nonmelanoma, nonepithelial)
  • Non-Hodgkin lymphoma 
  • Liver 
  • Anus 
  • Vulva 
  • Lip 

Other common malignancies with a statistically significant (p<0.001) increase included 

  • Lung 
  • Kidney 
  • Colon and rectum 
  • Pancreas 
  • Hodgkin's lymphoma 
  • Melanoma 

Pathophysiology

Transplant-related malignancies arise from an interplay of immunologic and nonimmunologic risk factors. The following is a brief description of the various pathways for the oncogenesis:

1. Immunosuppressive agents and oncogenesis: calcineurin inhibitors stimulate carcinogenesis by inhibiting DNA repair mechanisms, apoptosis, and enhancing the production of production of interleukin 2 (IL-2), transforming growth factor (TGF), and vascular endothelial growth factor (VEGF). Transforming growth factor promotes tumor growth by regulating tumor cell invasion, metastatic potential, and VEGF stimulates neo-angiogenesis. Azathioprine increases cancer risk by causing post-replicative DNA mismatch repair. Sirolimus, everolimus and mycophenolate mofetil are not associated with an increased risk of cancer; they actually have antiproliferative properties.

2. Viral Infection and oncogenesis: Transplant patients are vulnerable to viral infection or reactivation of latent infection. EBV promotes the oncogenesis by reduced lymphocyte regulation, a lack of control of the oncogenic virus by EBV-specific CD81 cytotoxic T-cells, and proliferation of EBV-infected B cells. The mechanism by which HHV-8 induces oncogenesis has not been completely elucidated. HHV-8’s proinflammatory proteins might directly inhibit apoptosis and promote cell transformation.[11]

History and Physical

Although early cancer diagnosis may show improvement of cancer outcomes in the cancer population, the reduced life expectancy and multiple comorbidities that exist in organ transplant recipients regular physical examination and history are of paramount importance. On average, the age at diagnosis of post-transplant cancer is 40 years and the time from transplantation is the 3 to 5 years.[12] However, these numbers vary according to the cancer subtype, with lymphoma and Kaposi sarcoma occurring early after transplantation and epithelial cancers later on. The specific questions on history taking that are of paramount importance are the amount of high sun exposure, any skin health concerns, and the onset of irregular skin lesions, as they all point towards the onset of skin malignancy. Studies have shown that continued consumption of alcohol and smoking lead to early and aggressive squamous cell malignancy and urinary bladder cancer. If there is a concern for fever, weight loss or any neurological disturbance, then radiological investigations should be performed to rule out PTLD. If the patient endorses lower GI bleed, then threshold to examine colon to rule out malignancy should be low. The history taking in patients with solid organ transplant is more vigorous and frequent than the general population. Physical examination should be carried out keeping in mind all the secondary cancers that may arise. Regular skin and breast examination should be performed in the office, a digital rectal exam to detect early prostate cancer, and neurological examination to clinically rule out CNS lymphoma and PTLD.[13]

Treatment / Management

Screening and early detection of cancers is the best form of treatment. Below are the recommendations for the screening of the specific malignancy.[14]

1. Breast cancer: Women 50 to 69 years: annual screening mammography with or without clinical breast examination is the current recommendation. At age 40 to 49 years: the benefit of screening is less certain and ultimate decision is up to the clinician and patient. In females above 70 years of age: annual screening is appropriate as long as estimated life expectancy is about 8 years.

2. Liver cancer: Patients with chronic hepatitis B or C and cirrhosis, serum AFP and liver ultrasound should be performed every 6 to 12 months.

3. PTLD: Complete history and physical examination should take place every three months, particularly in the first posttransplant year.

4. Anogenital: Early physical examination of the anogenital area, including a pelvic examination and cytologic studies for women. There is insufficient evidence to recommend either for or against screening anoscopy and biopsies of the anal epithelium.

5. Cervical: All women aged above 18 years and sexually active girls <18 years old should undergo an annual pelvic examination and Pap smear.

6. Skin cancers: Examination of skin, conjunctivae, and oropharyngeal mucosa annually; patients at higher risk (ethnicity, geographic area of residence or serologic positivity for HHV) may benefit from more frequent screening.

 Careful screening of the patient and donor before transplantation to help detect an underlying pre-existing malignancy is one of the effective ways to avoid dealing with this enigmatic problem later on. We have tried to summarize the broad topic of management and cancer in solid organ recipients into general recommendations;

1. Reduction of immunosuppression: Reduction or cessation of immunosuppressive therapy is useful primarily in patients who had a renal transplant since the loss of the graft to rejection is not a fatal event in these patients. Such measures may cause tumor regression sometimes such as  PTLD, some skin cancers, Kaposi sarcoma (KS).[15] The reduction in calcineurin inhibitor exposure may be important.

2. Anogenital cancers: In situ anogenital cancers can be treated with laser therapy, electrocautery, or topical fluorouracil. Invasive tumors require wide local excision (e.g., APR), with inguinal lymphadenectomy.

3. Visceral malignancy: Visceral malignancies are to receive treatment by standard surgical, radiotherapeutic, or chemotherapeutic modalities. 

4. Post-transplant lymphoproliferative disorder (PTLD): Management of PTLD deserves special mention as the treatment has undergone major changes over time. The main options for initial treatment are the reduction of immunosuppression, immunotherapy with the CD20 monoclonal antibody (rituximab), chemotherapy, radiation therapy, or a combination of these. The PTLD classifies into four types and treatment varies according to the type.

a) Early lesions:  Reduction of immunosuppression alone suffices.

b) Polymorphic PTLD: They express CD20, so besides the reduction in immunosuppression rituximab is advised. Surgery is reserved for patients with minimal localized residual disease.

c) Monomorphic PTLD: For CD20+ PTLD, reduction in immunosuppression with rituximab and combination of systemic chemotherapy such as CHOP (cyclophosphamide, vincristine, prednisone) is the therapeutic recommendation. If the tumor is CD20 negative, then systemic chemotherapy is administered along with the reduction in immunosuppression. Surgery is only for patients with complications such as perforation or obstruction of the hollow viscus such as the bowel. 

 d) Classic Hodgkin lymphoma-like PTLD–Classic Hodgkin lymphoma-like PTLD is the least common form data regarding its management is lacking. Treatment is according to the protocols used for classic Hodgkin lymphoma.[16][17]

Differential Diagnosis

Differential diagnosis:

1. PTLD: Infectious complications streptococcal pharyngitis and Infectious mononucleosis in an immunosuppressed individual presenting with fever, pharyngitis, and cervical lymphadenopathy closely mimic PTLD. Solid organ recipients with opportunistic pulmonary infections such as aspergillosis and acute graft-versus-host disease may develop multiple lung parenchymal nodules and alveolar opacities that mimic PTLD on imaging studies. 

2. Melanoma: Mucosal fungal lesions closely mimic mucosal melanoma, so the progression of lesion and cytology may be necessary to treat.

3. Skin cancers: keratoacanthoma and solar (actinic) keratosis closely mimic squamous cell carcinoma; an excisional biopsy can differentiate between the two. 

4. CNS Lymphoma: CMV or Toxoplasma are common viral and parasitic infections in an immunosuppressed individual, they present as ring-enhancing lesions in the brain and may be mistaken for primary or secondary CNS lymphoma.

5.  Benign conditions of the transplanted kidney, liver, and lungs can manifest as space-occupying lesions and mimic posttransplant malignancies. Renal pathologic conditions such as transplant-related fibrosis, acute pyelonephritis, and subcapsular hematoma may mimic malignancies at US and CT.

6.  Ischemia and reperfusion injury to the liver transplant may cause biliary necrosis and hepatic infarcts or micro-abscesses that may mimic recurrent HCCs at imaging studies.[18]

Prognosis

Malignant neoplasms after transplantation have different clinical features that are responsible for higher mortality. The Israel Penn International Transplant Tumor Registry showed that the stage-specific survival for cancer of colon, lung, breast, prostate, and bladder, was lower in patients after solid organ transplant compared with those without it. The 1-year adjusted survival of recipients with colorectal, prostate and non-small-cell lung cancer were 10%, 40%, and 20%, respectively, compared with 40%, 80%, and 30% in the general population.[19] Farrugia et al. reported that the overall risk of cancer death after transplantation was tenfold as compared to age- and sex-matched population.[20]

Complications

Complications because of post-transplant cancer are decreased quality of life, death, and increased healthcare spending.

Deterrence and Patient Education

The solid organ recipients should be counseled and taught to remain vigilant of this potential problem. The National Kidney Foundation conducted a survey whether transplant recipients remembered receiving information about the risk of cancer and other complications. The results were not promising as only one-third of these patients recalled receiving information from a health care professional about cancer risks before the procedure. One fourth (23%) of all the patients learned about the risk of post-transplant cancer only after their surgery. Filling this void a priority and detailed conversation before transplant and on follow-up visits need to take place. The patients should receive counseling regarding the risk factors that can be controlled or manipulated (e.g., immunosuppressive drugs, untreated viral infections), there is a window of opportunity to prevent post-transplant cancers. Thus, lies the importance of constant patient education.[21] Providing education and screening tools for all patients in the postoperative period ensures an extension of the provider's knowledge into the hands of the patients.

Enhancing Healthcare Team Outcomes

Successful organ transplantation and good quality of life for patients requires all members of the healthcare team to work together to provide bedside care, education, physical and psychosocial support, and continued follow-up examinations. Educating residents, organ transplant coordinators, nurses, and midlevel practitioners on the latest research are vital in promoting the best perioperative and postoperative care.[22]

Cancer screening and surveillance should be standard practice for healthcare policies in clinics and hospitals. All members of the team should be made aware of dermatological inspections, sun protection programs, and self-screening tools for all patients as a protocol in the posttransplant period. All the protocols should be standardized.[23]


Interested in Participating?

We are looking for contributors to author, edit, and peer review our vast library of review articles and multiple choice questions. In as little as 2-3 hours you can make a significant contribution to your specialty. In return for a small amount of your time, you will receive free access to all content and you will be published as an author or editor in eBooks, apps, online CME/CE activities, and an online Learning Management System for students, teachers, and program directors that allows access to review materials in over 500 specialties.

Improve Content - Become an Author or Editor

This is an academic project designed to provide inexpensive peer-reviewed Apps, eBooks, and very soon an online CME/CE system to help students identify weaknesses and improve knowledge. We would like you to consider being an author or editor. Please click here to learn more. Thank you for you for your interest, the StatPearls Publishing Editorial Team.

Cancer, Posttransplantation - Questions

Take a quiz of the questions on this article.

Take Quiz
Which of the following cancers is most common in patients who undergo transplants or receive chemotherapy?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up

Cancer, Posttransplantation - References

References

Pilmore H,Dent H,Chang S,McDonald SP,Chadban SJ, Reduction in cardiovascular death after kidney transplantation. Transplantation. 2010 Apr 15;     [PubMed]
Grulich AE,van Leeuwen MT,Falster MO,Vajdic CM, Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet (London, England). 2007 Jul 7;     [PubMed]
Vajdic CM,van Leeuwen MT, Cancer incidence and risk factors after solid organ transplantation. International journal of cancer. 2009 Oct 15;     [PubMed]
Acuna SA,Huang JW,Daly C,Shah PS,Kim SJ,Baxter NN, Outcomes of Solid Organ Transplant Recipients With Preexisting Malignancies in Remission: A Systematic Review and Meta-Analysis. Transplantation. 2017 Mar;     [PubMed]
Faure S,Herrero A,Jung B,Duny Y,Daures JP,Mura T,Assenat E,Bismuth M,Bouyabrine H,Donnadieu-Rigole H,Navarro F,Jaber S,Larrey D,Pageaux GP, Excessive alcohol consumption after liver transplantation impacts on long-term survival, whatever the primary indication. Journal of hepatology. 2012 Aug;     [PubMed]
Starr SP, Immunology Update: Long-Term Care of Solid Organ Transplant Recipients. FP essentials. 2016 Nov;     [PubMed]
Sprangers B,Nair V,Launay-Vacher V,Riella LV,Jhaveri KD, Risk factors associated with post-kidney transplant malignancies: an article from the Cancer-Kidney International Network. Clinical kidney journal. 2018 Jun;     [PubMed]
Penn I, Malignant melanoma in organ allograft recipients. Transplantation. 1996 Jan 27;     [PubMed]
Stallone G,Infante B,Grandaliano G, Management and prevention of post-transplant malignancies in kidney transplant recipients. Clinical kidney journal. 2015 Oct;     [PubMed]
Witherow BA,Roth GS,Carrozza MA,Freyberg RW,Kopke JE,Alloway RR,Buell JF,First MR,Gross TG,Hanaway MJ,Trofe J,Woodle ES,Beebe TM, The Israel Penn International Transplant Tumor Registry. AMIA ... Annual Symposium proceedings. AMIA Symposium. 2003;     [PubMed]
Martinez OM,de Gruijl FR, Molecular and immunologic mechanisms of cancer pathogenesis in solid organ transplant recipients. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2008 Nov;     [PubMed]
Chapman JR,Webster AC,Wong G, Cancer in the transplant recipient. Cold Spring Harbor perspectives in medicine. 2013 Jul 1;     [PubMed]
European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.6.3. Cancer risk after renal transplantation. Solid organ cancers: prevention and treatment. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2002;     [PubMed]
Acuna SA,Huang JW,Scott AL,Micic S,Daly C,Brezden-Masley C,Kim SJ,Baxter NN, Cancer Screening Recommendations for Solid Organ Transplant Recipients: A Systematic Review of Clinical Practice Guidelines. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2017 Jan;     [PubMed]
Penn I, Incidence and treatment of neoplasia after transplantation. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation. 1993 Nov-Dec;     [PubMed]
Zafar SY,Howell DN,Gockerman JP, Malignancy after solid organ transplantation: an overview. The oncologist. 2008 Jul;     [PubMed]
Al-Mansour Z,Nelson BP,Evens AM, Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies. Current hematologic malignancy reports. 2013 Sep;     [PubMed]
Katabathina VS,Menias CO,Tammisetti VS,Lubner MG,Kielar A,Shaaban A,Mansour J,Surabhi VR,Hara AK, Malignancy after Solid Organ Transplantation: Comprehensive Imaging Review. Radiographics : a review publication of the Radiological Society of North America, Inc. 2016 Sep-Oct;     [PubMed]
Wong G,Chapman JR,Craig JC, Death from cancer: a sobering truth for patients with kidney transplants. Kidney international. 2014 Jun;     [PubMed]
Farrugia D,Mahboob S,Cheshire J,Begaj I,Khosla S,Ray D,Sharif A, Malignancy-related mortality following kidney transplantation is common. Kidney international. 2014 Jun;     [PubMed]
Kauffman HM,Cherikh WS,Cheng Y, Posttransplantation malignancies: a problem, a challenge, and an opportunity. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 2002 May;     [PubMed]
Rashti SL, Themes in Literature Related to Incidence, Risk, and Prevention of Cancer in Solid-Organ Transplantation Recipients on Immunosuppressive Therapy. Cancer nursing. 2019 Jan/Feb;     [PubMed]
Hall EC,Pfeiffer RM,Segev DL,Engels EA, Cumulative incidence of cancer after solid organ transplantation. Cancer. 2013 Jun 15;     [PubMed]

Disclaimer

The intent of StatPearls is to provide practice questions and explanations to assist you in identifying and resolving knowledge deficits. These questions and explanations are not intended to be a source of the knowledge base of all of medicine, nor is it intended to be a board or certification review of CNS-Adult Health. The authors or editors do not warrant the information is complete or accurate. The reader is encouraged to verify each answer and explanation in several references. All drug indications and dosages should be verified before administration.

StatPearls offers the most comprehensive database of free multiple-choice questions with explanations and short review chapters ever developed. This system helps physicians, medical students, dentists, nurses, pharmacists, and allied health professionals identify education deficits and learn new concepts. StatPearls is not a board or certification review system for CNS-Adult Health, it is a learning system that you can use to help improve your knowledge base of medicine for life-long learning. StatPearls will help you identify your weaknesses so that when you are ready to study for a board or certification exam in CNS-Adult Health, you will already be prepared.

Our content is updated continuously through a multi-step peer review process that will help you be prepared and review for a thorough knowledge of CNS-Adult Health. When it is time for the CNS-Adult Health board and certification exam, you will already be ready. Besides online study quizzes, we also publish our peer-reviewed content in eBooks and mobile Apps. We also offer inexpensive CME/CE, so our content can be used to attain education credits while you study CNS-Adult Health.